Department of Molecular and Cellular Biology, Wroclaw Medical University, Borowska 211A, 50-556 Wroclaw, Poland.
Molecules. 2022 Feb 15;27(4):1303. doi: 10.3390/molecules27041303.
Until thirty years ago, it was believed that extracellular vesicles (EVs) were used to remove unnecessary compounds from the cell. Today, we know about their enormous potential in diagnosing and treating various diseases. EVs are essential mediators of intercellular communication, enabling the functional transfer of bioactive molecules from one cell to another. Compared to laboratory-created drug nanocarriers, they are stable in physiological conditions. Furthermore, they are less immunogenic and cytotoxic compared to polymerized vectors. Finally, EVs can transfer cargo to particular cells due to their membrane proteins and lipids, which can implement them to specific receptors in the target cells. Recently, new strategies to produce ad hoc exosomes have been devised. Cells delivering exosomes have been genetically engineered to overexpress particular macromolecules, or transformed to release exosomes with appropriate targeting molecules. In this way, we can say tailor-made therapeutic EVs are created. Nevertheless, there are significant difficulties to solve during the application of EVs as drug-delivery agents in the clinic. This review explores the diversity of EVs and the potential therapeutic options for exosomes as natural drug-delivery vehicles in oncology, neurology, and dermatology. It also reflects future challenges in clinical translation.
直到三十年前,人们还认为细胞外囊泡 (EVs) 的作用是从细胞中清除不必要的化合物。如今,我们已经了解到它们在诊断和治疗各种疾病方面的巨大潜力。EVs 是细胞间通讯的重要介质,能够实现生物活性分子从一个细胞到另一个细胞的功能转移。与实验室制造的药物纳米载体相比,它们在生理条件下更稳定。此外,与聚合载体相比,它们的免疫原性和细胞毒性更低。最后,由于其膜蛋白和脂质,EVs 可以将货物转移到特定的细胞,这可以使它们与靶细胞中的特定受体结合。最近,已经设计出了生产特定外泌体的新策略。通过基因工程使递送外泌体的细胞过表达特定的大分子,或者将其转化为释放具有适当靶向分子的外泌体。通过这种方式,我们可以说定制治疗性 EVs 已经被创造出来了。然而,在将 EVs 作为药物递送剂应用于临床时,仍然存在着重大的困难需要解决。这篇综述探讨了 EVs 的多样性,以及外泌体作为天然药物递送载体在肿瘤学、神经学和皮肤病学中的潜在治疗选择。它还反映了临床转化中的未来挑战。